ASLAN Pharmaceuticals Announces Acceptance of Late-Breaking Abstract on Eblasakimab Proof-of-Concept Study in Atopic Dermatitis for Oral Presentation at the 2022 American Academy of Dermatology Annual Meeting

Rhea-AI Summary

ASLAN Pharmaceuticals (NASDAQ: ASLN) has announced that key efficacy and safety data from its eblasakimab Phase 1b study will be presented at the 2022 American Academy of Dermatology Annual Meeting on March 26. This randomized, double-blinded, placebo-controlled study focused on treating adult patients with moderate-to-severe atopic dermatitis. Eblasakimab is a novel monoclonal antibody targeting the IL-13 receptor, with the potential to offer improved safety and efficacy profiles.

Positive

• Efficacy and safety data from the Phase 1b study of eblasakimab accepted for late-breaking oral presentation.
• Eblasakimab has a unique mechanism targeting IL-13 receptor, which could improve treatment outcomes.

Negative

• None.

- Topline data from the eblasakimab Phase 1b multiple-ascending-dose study will be presented during the “Late-breaking Research: Clinical Trials” session at the 2022 American Academy of Dermatology Annual Meeting on March 26

MENLO PARK, Calif. and SINGAPORE, March 18, 2022 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that an abstract highlighting key efficacy and safety data from the completed Phase 1b study for eblasakimab (ASLAN004) in atopic dermatitis (AD) has been accepted for late-breaking oral presentation at the 2022 American Academy of Dermatology Annual Meeting, to be held in-person March 25-29, 2022, in Boston, Massachusetts.

2022 American Academy of Dermatology Annual Meeting oral presentation details

Title: Eblasakimab, a human anti-IL-13 receptor monoclonal antibody, in adult patients with moderate-to-severe atopic dermatitis: a randomized, double-blinded, placebo-controlled, proof-of-concept study

Presentation time: March 26, 2022, 9:00 AM - 9:10 AM

Presenter: Dr Andrew Blauvelt, President, Oregon Medical Research Center

Session: Late-breaking Research: Clinical Trials

Location: Room 210A

Media and IR contacts

Emma Thompson  Spurwing Communications  Tel: +65 6206 7350  Email: ASLAN@spurwingcomms.com

Ashley R. Robinson  LifeSci Advisors, LLC  Tel: +1 (617) 430-7577 Email: arr@lifesciadvisors.com

About eblasakimab (ASLAN004)
Eblasakimab, also known as ASLAN004, is a novel, potential first-in-class monoclonal antibody that targets the IL-13 receptor α1 subunit (IL-13Rα1), one of the components of the Type 2 receptor. By blocking the Type 2 receptor, eblasakimab prevents signaling through both interleukin 4 (IL-4) and interleukin 13 (IL-13) – the key drivers of inflammation in atopic dermatitis. The unique mechanism of action has the potential to deliver a differentiated safety and efficacy profile as well as an improved dosing regimen

About ASLAN Pharmaceuticals
ASLAN Pharmaceuticals (Nasdaq:ASLN) is a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. ASLAN is currently evaluating eblasakimab, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. ASLAN has a team in Menlo Park, California, and in Singapore. For additional information please visit www.aslanpharma.com or follow ASLAN on LinkedIn. 

FAQ

What is the significance of the eblasakimab Phase 1b study presented by ASLAN Pharmaceuticals?

The Phase 1b study data for eblasakimab highlights its efficacy and safety in treating moderate-to-severe atopic dermatitis, which is crucial for validating its potential as a new treatment.

When will the eblasakimab study data be presented?

The data will be presented during the Late-breaking Research session on March 26, 2022, at the American Academy of Dermatology Annual Meeting.

Who is presenting the eblasakimab study findings?

Dr. Andrew Blauvelt, President of Oregon Medical Research Center, will present the findings.

What type of study design was used for eblasakimab Phase 1b clinical trial?

The study was a randomized, double-blinded, placebo-controlled proof-of-concept trial.

What is the mechanism of action of eblasakimab?

Eblasakimab targets the IL-13 receptor α1 subunit, blocking signaling through IL-4 and IL-13, which are key drivers of inflammation in atopic dermatitis.